Effect of Intact GLP-1 (7-36) and GLP-1 Metabolite (9-36) on Coronary and Peripheral Vascular Function in Adults

• Status: Completed
• Trial end date: 2018-06-01
• Target enrollment: 0
• Participant gender: All

Summary

GLP-1 is an agent for treatment of type 2 diabetes and may have protective effects on the cardiovascular system. The mechanism is complex and there seems to be a dual function with intact GLP-1 (7-36), acting through the GLP-1 receptor, and the GLP-1 (9-36) metabolite acting independently of the GLP-1 receptor.

Coronary flow reserve (CFR) is the ratio of flow through the coronary arteries during stress to during rest and it reflects coronary microcirculation. Impaired CFR is a strong predictor of poor prognosis of cardiovascular disease.

The aim of the study is to investigate the acute effects of GLP-1 on coronary microcirculation and endothelial function in adults with obesity.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Mette Zander
• Collaborator: Hvidovre University Hospital
• Treatments: Glucagon-Like Peptide 1

Criteria

Inclusion Criteria:

• Age 35-70 years

• BMI > 25 kg/m2.

• Central obesity (measured by waist circumference, defined as ≥ 94cm for men and ≥ 80 cm for women)

• Non smokers (6 months abstinent is required)

• Normal creatinine

• For fertile women; negative pregnancy test and use of safe anticonception.

• Speak and understand Danish or English

• Mental ability to follow and understand the study

Exclusion Criteria:

• Known Diabetes

• Known hypertension (untreated hypertension ≤ 160/100 at inclusion is accepted)

• Haemoglobin < 6.5 mmol/l

• Allergy towards Januvia or Exenatide, Adenosin or Glycerylnitrate

• Documented significant stenosis of the left anterior descending artery (LAD) at coronary angiography or CT-angiography or regional dysfunction documented during dipyridamol stress-echocardiography. If stress test at baseline shows significant stenosis the patient will be excluded from the study.

• Pregnancy

• Severe asthma

• Active cancer, severe co-morbidity with limited life-expectancy, severe hepatic co-morbidity, chronic alcohol abuse, atrial fibrillation, chronic or previous acute pancreatitis, inflammatory bowel disease.